
Project Director: Diego A Adrianzen, M.D.
Assistant Professor of Medicine
Department of Medicine-Hematology Oncology
University of Vermont
Project: Risk Prediction and Inflammatory Biomarkers of Cardiovascular Disease in Myelodysplastic Syndromes
Project Description
Myelodysplastic Syndromes (MDS) are blood cancers caused by acquired mutations in cells of the bone marrow that give rise to blood cells (bone marrow progenitors). These mutations also cause excess inflammation in blood vessels and risk of cardiovascular diseases (CVDs), which are a large source of complications and mortality in patients with MDS. Dr. Adrianzen Herrera’s previous work has described that MDS patients have a high risk for CVD and death from CVD. His current project has two goals. First, he will develop and validate a clinical tool to predict risk of CVD in patients with MDS. Second, he will study biomarker changes in the blood in people with MDS. The ultimate goal is to understand why people with MDS develop CVD and how this can be prevented.
Project Figure

PDF describing image: Role of myelodysplastic syndromes in cardiovascular disease
Project Mentorship Team
Senior Mentor
Neil Zakai, MD, MSc
Senior Mentor
Ira Bernstein, MD
Peer Mentor
Nels Olson, PhD
External Mentor
Pamela Lutsey, PhD, MPH

Project Director: David Punihaole, Ph.D.
Assistant Professor
Department of Analytical Chemistry, Physical Chemistry, Biophysical Chemistry
University of Vermont
Project: Determining How Amyloid-Beta Fibril Polymorphism Influences Cellular Toxicity
Project Description
Cerebral Amyloid Angiopathy (CAA) and Alzheimer’s Disease (AD) are debilitating diseases that can lead to memory loss, cognitive decline and dementia. A pathological hallmark of CAA and AD is the formation of plaques composed of amyloid-β (Aβ) fibrils in blood vessels and brain. Structural variants of fibrils, termed polymorphs, have been detected in human tissues and are thought to contribute differently to the pathophysiology of these diseases. However, the causal relationship between fibril structure and cellular toxicity remains largely unknown. To evaluate this relationship, we will use novel chemical imaging and electrochemical sensing methods to directly monitor the structural dynamics, aberrant interactions, and toxic activities of different Aβ fibril polymorphs in human tissues and animal models of CAA. Successful completion of this project will ultimately provide information that guides the rational design of drugs to limit the formation and toxic interactions of Aβ fibril polymorphs in people with CAA and AD.
Project Figure
Project Mentorship Team
Senior Mentor
Marilyn Cipolla, PhD
Senior Mentor
Mark Nelson, PhD
Peer Mentor
Osama Harraz, PhD
External Mentor
Jennifer Lee, PhD